PPHM Priorities per resources: “CANCER=NOW; viral=later”, but Bavi/AV research clearly continuing in the background via UTSW/UK-PHE/Duke (NIAID?) collab’s with Peregrine researchers. Examples…
10-2012: NIAID is “particularly interested how PS & PE expression… which is key to regulation of the immune response.” http://tinyurl.com/mvzqn26 …the above from John Coligan’s (PhD, Chief, Receptor Cell Biology Section) NIAID lab webpage. NIAID - Laboratory of Immunogenetics John E. Coligan, PhD - Chief, Receptor Cell Biology Section, LIG http://www.niaid.nih.gov/LabsAndResources/labs/aboutlabs/lig/receptorCellBiologySection/Pages/coligan.aspx Program Description (webpage last upd. 10-26-2012) Excerpts: “We are excited about our studies on the CD300 receptors… In addition to this work on phagocytosis, studies on the other potential biological functions of the CD300 receptors will be a major part of our future research. We are particularly interested how PS & PE expression on activated/apoptotic cells regulates the interactions between stimulated T & B cells and myeloid cells (dendritic cells and macrophages), which is key to regulation of the immune response… Also, mouse CLM-3 & CLM-5 are putative activation receptors closely related to mouse CD300f, and it will be interesting to determine if they preferentially bind PS.”
= = = = = = = = = = = = = = = = 11-16-2012: 'Antiviral-Research' article by Bavi-AV collaborator HPA/UK & PPHM researchers on Bavi vs. EBOLA …"Virus induced externalization of PS raises the possibility that PGN401 (Bavi) has broad spectrum antiviral activity." http://investorshub.advfn.com/boards/read_msg.aspx?message_id=81719282
= = = = = = = = = = = = = = 9-3-2014: Public-Health-England/PPHM article on Bavi/Ebola in Hindawi’s Journal-of-Immunology-Research 10-15-14/PR: Bavi/Ebola-Binding article in peer-reviewed Journal-of-Immunology-Research (“Vaccines & Therapies for Biodefense Agents” special edition) – submitted=2/25/14, Rev=6/20/14, Accepted=9/3/14 – authors are Public Health England & PPHM researchers… "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions." http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107223603 …Jeff Hutchins (VP/PreClinRES) 10-15-14: “We have a number of active collaborations exploring the potential of PS-targeting antibodies in infectious diseases… While our primary focus remains on advancing Bavi in oncology…, we believe these data warrant further collaborative investigation in Ebola and other infectious diseases including combinations with vaccines and active therapies that have shown promise." …Cyril Empig (AssocResDIR) 10-15-14: ”We believe that there are advantages to utilizing Bavi in a treatment regimen against Ebola virus given its great specificity for Ebola virions & Ebola-infected cells, its potential to circumvent the problem of virus escape mutations given that it is targeting a host molecule rather than a virus protein or protein sequence, and the possible role of PS in immunosuppression during Ebola infection. Given these data, we are developing a plan to explore potential applications of bavituximab and PS-targeting antibodies in the treatment of Ebola."
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = ALSO ON THE BAVI/INFECTIOUS SIDE (HIV)… 3-2014: Keystone Conf./Alberta PS-Targeting/HIV Poster by PPHM’s Cyril Empig & Duke/Peregrine Co-Authors Haynes/Moody/etc http://tinyurl.com/m6kuqpr …”We expanded the characterization of PGN632 in the current study; PGN631 & PGN633, “sister clones” of PGN632, are also able to inhibit HIV-1 in the PBMC assay.” - - - - - - - - - - 4-11-2010: CHAVI Newsletter highlights PPHM-Duke JEM article http://tinyurl.com/35eelvw (Haynes/Moody/Thorpe/King...) ..."The study is significant because it shows that components of the adaptive immune system can activate antiviral innate immunity. Investigators believe that a vaccine that elicits polyreactive anti-PS antibodies could potentially be used to engage both the innate and adaptive immune response against HIV." 4-5-10 JEM article (23pgs) by Haynes/Moody/Thorpe/S.King/P.Chen/etal, “Anti-phospholipid Human Monoclonal Antibodies Inhibit CCR5-tropic HIV-1 and Induce B-chemokines”http://www.ncbi.nlm.nih.gov/pubmed/20368576
- - - - - - -RECALL: • PGN635 (B2GPI-dep.) is Fully-Human Bavituximab=1N11=AT004 (B2GPI-depen.); Genentech studying 89Zr-PGN635 as a Tumor Imaging Agent, “indep. of cancer type” • PGN632 (B2GPI-indep.) is the Duke-PPHM-HIV candidate=11.31=AT005; also being studied by PPHM+LSU vs. Ocular Herpes (Acute HSV-1 Keratitis), see http://tinyurl.com/cax9a4p AND NOW WE HAVE 2 PGN632 “Sister Clones” being jointly studied by Duke&PPHM in HIV studies: • PGN631 - Sister clone of PGN632, also able to inhibit HIV-1 in the PBMC assay • PGN633 - Sister clone of PGN632, also able to inhibit HIV-1 in the PBMC assay Evaluate-Ltd: Product: PGN633”HIV vaccine” Therapeutic Subcat: Vaccines http://www.evaluategroup.com/View/62065--1002-modData/product/pgn633
Thank you very much. Bavituximab(Bavi) has been shown safe in 600 patients and effective against Ebola in vitro. It shows promise not only in treating ebola but as a prophylactic prior to Ebola exposure. I don't understand why our US personnel have not been offered a shot of Bavi prior to going to the front lines in the Ebola fight. PPHM.
News 
Market Data 
Discover 
